Herc Holdings Inc
Trading Companies & Distributors
Herc Holdings Inc (HRI) Stock News
The latest HRI headlines and market coverage — 4 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
DBV Technologies announced positive Phase 3 VITESSE study results showing the VIASKIN® Peanut Patch demonstrated statistically significant efficacy versus placebo in children aged 4-7 years with peanut allergy who also have atopic comorbidities such as asthma, food allergies, or atopic dermatitis. The company also previewed its newly initiated Phase 2 THRIVE study, which will evaluate the patch's efficacy in infants aged 6-12 months with peanut allergy over three years of treatment.
- GlobeNewswire Inc.·
DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion du Congrès de l’EAACI 2026
DBV Technologies announced positive results from its Phase 3 VITESSE study showing that the VIASKIN® Peanut patch demonstrated statistically significant efficacy versus placebo in peanut-allergic children aged 4-7 years with concurrent atopic conditions including asthma, food allergies, and atopic dermatitis. The company also presented the design of its Phase 2 THRIVE study evaluating the patch in infants aged 6-12 months with peanut allergy, aiming to enable unrestricted peanut consumption after three years of treatment.
- GlobeNewswire Inc.·
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
DBV Technologies announced the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants ages 6-12 months with peanut allergy. The study will assess whether the patch can enable ad lib (unrestricted) peanut consumption through epicutaneous immunotherapy (EPIT), building on positive results from earlier trials in older age groups.
- GlobeNewswire Inc.·
DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide
DBV Technologies announced the first participant screening in the THRIVE phase 2 clinical trial evaluating the efficacy and safety of VIASKIN® Peanut patch in infants aged 6-12 months with peanut allergies. The study aims to enable ad libitum peanut consumption through early intervention immunotherapy, building on positive results from earlier trials in older children.